Introducing a frameshift mutation to the POL sequence of HIV-1 provirus and evaluation of the immunogenic characteristics of the mutated virions (RINNL4-3).
Inactivation of the reverse transcriptase (RT) and integrase (IN) enzymes can abolish the replication of the human immunodeficiency virus (HIV) and, thus, its infectivity. Here, inactivated HIV particles convenient for designing virus-like particle (VLP) based vaccines have been produced. Inactivated HIV-provirus was created by introducing a frame shift mutation. HIV provirus DNA was cut in the pol region by Age I restriction enzyme, followed by filling of sticky ends using the Klenow fragment before ligation. The resulting plasmid was named as pRINNL4-3. HEK-293T cells were used as producer, after being transfected with the modified plasmid. Viral particle production and biological activity were assayed by virus capsid protein (p24) quantification and syncytium formation in MT2 cells, respectively. The immunogenicity of the RINNL4-3 virions was investigated in a mouse model. The mutation was expected to inactivate the virus RT and IN enzymes. The results showed that the VLPs were assembled, as measured by the p24 load of the culture supernatant, and contained functional envelope proteins (Env) as monitored by the syncytium formation. However, these VLPs had no ability to infect target MT2 cells, as well as their VSVG (vesicular stomatitis virus-glycoprotein) pseudotyped counterparts infected HEK-293T cells. A high level of antibody response was observed in immunized mice. Since RINNL4-3 virions are replication incompetent, they are convenient for production and use in biomedical studies. Also, RINNL4-3 is a candidate for a vaccine development due to it contains envelope and structural virus proteins which are crucial for triggering neutralizing antibodies and the cellular immune response.
Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran. Rezvan_z_m@yahoo.com
Rezvan
R
Zabihollahi
Seyed Mehdi
SM
Sadat
Rouhollah
R
Vahabpour
Mansoor
M
Salehi
Kayhan
K
Azadmanesh
Seyed Davar
SD
Siadat
Ali Reza Azizi
AR
Saraji
Mohamamd Hassan
MH
Pouriavali
Seyed Bahman
SB
Momen
Mohamad Reza
MR
Aghasadeghi
D016915:AIDS Vaccines / Q000235:genetics / Q000276:immunology*; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology; D005260:Female; D016368:Frameshift Mutation; D015686:Gene Products, env / Q000096:biosynthesis; D057809:HEK293 Cells; D016655:HIV Core Protein p24 / Q000096:biosynthesis; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D019427:HIV Integrase / Q000235:genetics / Q000276:immunology; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors / Q000235:genetics / Q000276:immunology; D015497:HIV-1 / Q000235:genetics* / Q000276:immunology; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D010957:Plasmids / Q000235:genetics / Q000276:immunology; D014162:Transfection; D058425:Vaccines, Virus-Like Particle / Q000235:genetics / Q000276:immunology*; D014771:Virion / Q000235:genetics / Q000276:immunology; D054302:pol Gene Products, Human Immunodeficiency Virus / Q000235:genetics* / Q000276:immunology
D016915:AIDS Vaccines; D000914:Antibodies, Viral; D015686:Gene Products, env; D016655:HIV Core Protein p24; D058425:Vaccines, Virus-Like Particle; C514799:p24 protein, Human Immunodeficiency Virus Type 1; D054302:pol Gene Products, Human Immunodeficiency Virus; D019427:HIV Integrase; D054303:HIV Reverse Transcriptase